ChAd63-KH

BIOLOGICAL2 trials

Sponsors

University of York

Conditions

Leishmaniasis, Cutaneous

Phase 2

A Study of a New Leishmania Vaccine Candidate ChAd63-KH

CompletedNCT02894008

University of YorkLeishmaniasis, Cutaneous

Start: 2016-11-30End: 2019-12-31Updated: 2020-01-28

A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

CompletedNCT03969134

University of YorkLeishmaniasis, Cutaneous

Start: 2020-04-06End: 2023-02-28Updated: 2023-05-26

Related Papers

A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis.

2024-07-30

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.

2022-08-0311 citations

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

Molecular Therapy2021-03-2761 citations